Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.9K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.9K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.0K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fosinopril: HIV-Associated Nephropathy (HIVAN).

Hospital pharmacy·2024
Same author

Idarucizumab.

Hospital pharmacy·2024
Same author

Fentanyl Iontophoretic Transdermal System.

Hospital pharmacy·2024
Same author

Fifty Years of Publication: Hospital Pharmacy Anniversary.

Hospital pharmacy·2024
Same author

Rolapitant.

Hospital pharmacy·2024
Same author

Zafirlukast: Chronic Urticaria.

Hospital pharmacy·2016

Related Experiment Video

Updated: Mar 19, 2026

Whole Body Vibration Methods with Survivors of Polio
04:16

Whole Body Vibration Methods with Survivors of Polio

Published on: October 17, 2018

9.3K

Pyridostigmine: Postpoliomyelitis Syndrome.

Joyce A Generali, Dennis J Cada

    Hospital Pharmacy
    |June 16, 2016
    PubMed
    Summary

    This guide helps healthcare professionals quickly find and evaluate literature on unapproved drug uses. It supports rational patient care decisions by referencing published studies on off-label drug applications.

    Area of Science:

    • Pharmacy
    • Pharmacology
    • Drug Utilization

    Background:

    • Off-label drug use refers to prescribing medications for conditions not approved by the US Food and Drug Administration (FDA).
    • Practitioners require reliable information to assess the safety and efficacy of these unapproved uses.
    • Existing literature on off-label drug applications can be fragmented and difficult to access.

    Purpose of the Study:

    • To provide a practitioner-oriented resource for information on off-label drug uses.
    • To enable healthcare professionals to identify and evaluate published studies on specific off-label drug applications.
    • To support rational patient care decisions by facilitating access to evidence on unapproved drug uses.

    Main Methods:

    • Extraction of relevant information from the publication 'Off-Label Drug Facts'.

    More Related Videos

    Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
    07:20

    Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

    Published on: August 9, 2024

    2.1K
    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
    06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    3.6K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Whole Body Vibration Methods with Survivors of Polio
    04:16

    Whole Body Vibration Methods with Survivors of Polio

    Published on: October 17, 2018

    9.3K
    Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
    07:20

    Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

    Published on: August 9, 2024

    2.1K
    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
    06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    3.6K
  • Compilation of literature references to support off-label drug use evaluations.
  • Focus on a practitioner-oriented approach for quick identification of studies.

    • Main Results:

    • A guide is available to help clinicians identify published studies on off-label drug uses.
    • The resource aids in determining the rationality of specific off-label uses in patient care.
    • References are provided for comprehensive literature review before making patient care decisions.

    Conclusions:

    • The 'Off-Label Drug Facts' publication serves as a valuable tool for healthcare professionals.
    • It enhances the ability to make informed decisions regarding unapproved drug uses.
    • Access to curated literature supports evidence-based practice in managing off-label drug applications.